By Tricitynews Reporter
Chandigarh
27th October:- Glenmark Pharmaceuticals
Limited, a research-led global integrated pharmaceutical company,
announced the launch of Apremilast in India. Apremilast is the first advanced
Oral Systemic treatment for Psoriasis in India. Apremilast is a
phosphodiesterase 4 (PDE4) inhibitor which is indicated for the treatment of
moderate to severe Psoriasis. The launch of Apremilast will revolutionize the
treatment of Psoriasis impacting close to 33 million Indians suffering from the
condition.
Apremilast
is an advanced oral treatment for Psoriasis which addresses the limitations of
the current available therapies in India. It acts in a targeted manner at an
early stage of the disease progression. Also, it is an immunomodulator whereas
the other available drugs in the country are immunosuppressant including
biologics and are mostly indicated for the treatment of oncological conditions.
Immunosuppressants suppress the immune system thereby making the body
susceptible to various infections. Apremilast being animmunomodulator does not
suppress the immune system and treats the condition of psoriasis at an
intracellular level which will benefit psoriasis patients across the country.
Apremilast
is an oral therapy which can be self-administered unlike currently available
injectable therapy which has to be administered by paramedics. Further,
Apremilast is a safer drug having no effects on other organs like the liver and
kidney and does not require routine laboratory diagnostic tests like CBC, liver
& Kidney test or TB screening as required in the case of other therapies
used currently.
Glenmark has launched Apremilast
under the brand name ‘Aprezo’ indicated for the treatment of
Psoriasis. Glenmark received approval from DCGI for Apremilast after conducting clinical
trials on the molecule as per the regulatory requirements.
Rajesh Kapur, Senior Vice President–Sales
& Marketing, Glenmark Pharmaceuticals, said that Apremilast
is a safe and efficacious treatment compared to the existing treatment
available in the country. Apremilast will be the only oral medicine available
in the country exclusively for Psoriasis. In addition to this, it also addresses
the several limitations of existing treatments like routine laboratory
monitoring. We hope that millions of patients in India will now be able to live
a better quality of life with this revolutionary treatment.
World
Psoriasis Day is a big event observed all over the world by the people to
increase the awareness among public worldwide with an aim to raise the profile
of this debilitating disease and increase awareness of the effect it has on
people’s lives. This event is organized on international level by the
International Federation of Psoriasis Associations and it is observed on annual
basis on 29th October.
Globally,
about 3% of the world population has some form of Psoriasis.
Another study reveals that the prevalence
of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis as
one of the serious global problems.
India
has now become one of the largest patient pool in the world and is estimated to
have around 33 million psoriasis patients. As per a study on psoriasis in
India, with data collected from various medical colleges located in Lucknow,
Dibrugarh, Calcutta, Patna, Darbhanga, New Delhi and Amritsar, it was found
that the incidence of psoriasis among total skin patients ranged between 0.44
and 2.2%. It was also found that the ratio of male to female (2.46:1) was very
high and highest incidence was noted in the age group of 20-39 years.
Apremilast will revolutionize the
treatment for 33 million psoriasis patients in the country. Apremilast is the
first oral treatment in India specific for psoriasis treatment; it is
convenient to administer, it is safer compared to existing therapies and will
transform the psoriasis treatment regime in the country.
No comments:
Post a Comment